28.06.2010 • News

Big Pharma Stocks Could Rally in the Next Year

Wall Street appears to be overly pessimistic about large pharmaceutical companies, and some of the stocks could rally 30% over the next year, according to a cover story in the June 28th edition of Barron's. Some of the best value lies in Merck & Co, Pfizer, Sanofi-Aventis, Novartis and Roche, according to the article in the weekly financial publication. Bristol-Myers Squibb, Eli Lilly and Astrazeneca do not look as attractive as some of their peers, the Barron's article said.

(6/28/2010)

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read